NIH's $26M Systems Biology Centers for Infection and Chronic Disease: Two Center Types, One February 18 Deadline, and No Foreign Subawards
November 16, 2026 · 8 min read
Granted Research Team · Editorial policy
There are two competitions inside this NIH call. Which one you enter decides your budget ceiling, your required cores, your review priorities, and whether you have to build a cohort or plug into one NIH already paid for.
RFA-AI-28-014, "Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)," was posted November 4, 2026. It opens for submission on January 18, 2027, and closes on February 18, 2027, at 5:00 p.m. local time. That is a single receipt date: the NOFO expires the next day. Peer review is in July 2027, council review in October 2027, and the earliest start date is January 2028. That timing is why the money is described as FY2028 funds.
The lead institute is the National Institute of Allergy and Infectious Diseases. The National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Heart, Lung, and Blood Institute, the National Institute of Dental and Craniofacial Research, and the National Eye Institute also participate. The NIH Office of Autoimmune Disease Research may cofund. Here is what the call funds, how the two center types differ, and how to avoid the four responsiveness traps that will remove applications before review.
The Scientific Premise
The call starts from a gap that the COVID-19 pandemic made obvious. Infections and chronic diseases interact in both directions, and almost no research program studies both at once. Diabetes and obesity change susceptibility to respiratory infections. Epstein-Barr virus is now strongly implicated in multiple sclerosis. Lyme disease and other infections can leave long-lasting post-acute syndromes. Chronic inflammation is a common thread linking cardiometabolic, neurodegenerative, autoimmune, and psychiatric disease.
NIH wants centers that combine "existing longitudinal patients cohorts," electronic health records and other real-world data, large multiomics datasets, and "advanced Artificial Intelligence (AI) and computational modeling." The centers must then validate what they find in the laboratory, using new approach methodologies (NAMs), animal models, and real-world data. The goals listed include new disease classifications based on shared molecular signatures, new drug targets and biomarkers, rational design of combination therapies, and harmonized cross-disease datasets built to FAIR principles.
This continues more than a decade of NIAID investment in systems biology for infectious disease, now aimed at chronic disease and strongly framed around AI. The emphasis on NAMs follows NIH's broader 2025 push to reduce reliance on animal models where human-based methods can do the job.
Two Center Types, Two Different Bets
Applications must be "primarily aligned with the goals and objectives of only one type of Center," and must say which one.
| Chronic and Infectious Diseases Systems Biology Center (CIDSB) | Systems Biology Inflammation Center (SBI) | |
|---|---|---|
| Lead funders | NIAID | NIA and NIAMS |
| Funds committed (FY2028) | $18.5 million | $6 million |
| Expected awards | 5 to 6 | 1 to 2 |
| Direct-cost cap | $2.5 million per year | Not capped (must match need) |
| Research Projects | Exactly 3 | At least 2 |
| Technology Development Core | Required | Optional |
| Validation and Translation Core | Required | Optional |
| Focus | Bidirectional links between infections and chronic disease | Inflammation across chronic diseases, built on AMP data |
NIDCR will add up to $1 million for projects in its mission area, and NEI $500,000 a year for eye-imaging integrated data. Together, that is about $26 million across 6 to 8 centers. Every award runs for five years.
CIDSB is the larger, more open competition. NIAID gives examples of chronic conditions, including inflammatory bowel disease, cancer, neurological, cardiovascular, and metabolic disease, and mental health disorders. It gives examples of infections "of high relevance in the United States": Lyme, influenza, RSV, tuberculosis, Epstein-Barr virus, and recurring or persistent infections such as pneumonia and urinary tract infections. NIAID's stated funding priorities favor applications that study the bidirectional interplay and those that include multiple pathogens and multiple chronic diseases. A center built around a single pathogen and a single disease can be funded, but it starts behind.
SBI is smaller and more tightly scoped. These centers must build on the Accelerating Medicines Partnership (AMP), NIH's public-private research consortium. The NOFO lists the programs to draw on: AMP AD 1.0 and 2.0 for Alzheimer's disease, AMP RA/SLE for rheumatoid arthritis and lupus, AMP AIM for autoimmune and immune-mediated diseases, AMP CMD for common metabolic diseases, AMP PD and AMP PDRD for Parkinson's disease and related disorders, and AMP T2D for type 2 diabetes. The research strategy must explain how the center will use AMP data and specimens and fill "critical multi-omic (bulk and single cell) data gaps using existing biosamples." The two lead institutes have different priorities. NIAMS favors autoimmune systemic, rheumatic, and skin diseases, combined with at least two of the neurodegenerative, neuropsychiatric, and cardiometabolic groups. NIA favors Alzheimer's disease combined with at least three of the neurodegenerative, neuropsychiatric, autoimmune, and cardiometabolic groups.
The SBI budget is uncapped for a reason. SBI applications must include an Opportunities Fund line in the Administrative Core of up to $2 million in direct costs a year in years 2 through 5, to support one to six collaborative projects a year. NIH will choose one SBI recipient to manage that fund "for the entire SBI program," and the applicant institution must provide a letter committing to administer it if selected. With $6 million split across one or two SBI awards, applicants should expect a single large SBI center and size the science to fit.
The Required Architecture
This is a multi-component U19 with a rigid structure and page limits for each component.
| Component | Page limit | Required? |
|---|---|---|
| Overall | 12 | Yes |
| Administrative Core | 6 | Yes |
| Data and Modeling Core | 12 | Yes |
| Technology Development Core | 6 | CIDSB yes, SBI optional |
| Validation and Translation Core | 12 | CIDSB yes, SBI optional |
| Biospecimen Collection and Processing Core | 6 | Yes |
| Research Projects (each) | 12 | 3 for CIDSB, 2 or more for SBI |
A full CIDSB application includes nine components and 90 pages of research strategy before biosketches, budgets, and human-subjects records. Two details matter in planning. First, the generic component table marks the Technology Development and Validation and Translation Cores as optional, but the NOFO text makes both mandatory for CIDSB. Read the program-specific instructions, not just the table. Second, the Data and Modeling Core gets 12 pages, the same as a Research Project. NIH expects real methods there, not a description of a service core.
The contact PD/PI must lead the Administrative Core with at least 0.6 person-months of effort. Budget for travel to a kickoff meeting and to annual programmatic meetings near Bethesda starting in year 2. A consortium-wide Scientific Advisory Group will be set up after award. Do not name or contact potential members in the application.
Four Ways to Be Returned Without Review
The NOFO lists four non-responsive categories. Each one rules out a common center design.
- No longitudinal human clinical samples with clinical data. Every center must use material from longitudinal human samples, such as cells, tissue, blood, immune components, or bacterial isolates, linked to clinical data. Centers based only on animal models or cross-sectional samples are out. Limited prospective cohort collection is allowed "to ensure sufficient data is available for model development and validation," but NIH plainly prefers existing cohorts.
- Pathogen-only network biology. Work that models only the pathogen's molecular interactions without the host side is not responsive.
- Tools-only computation. Applications that "focus solely on development of computational and software tools for 'big-data' integration" will not be reviewed. AI is central to the call, but it must serve hypothesis-driven biology.
- HIV/AIDS. Excluded entirely.
Two eligibility rules also need early attention. Foreign organizations cannot apply, and foreign subawards are not allowed. NIH stopped issuing awards with foreign subawards in 2025, and applications that include them "will be deemed noncompliant." Foreign components without subawards are still allowed, as are unfunded international collaborations, foreign consultants, and unique foreign supplies. A center that planned to fund a European cohort partner through a subaward must restructure. Data access agreements and consultant arrangements are the usual alternatives.
Eligibility is otherwise broad: universities, nonprofits, for-profits, governments, and tribal organizations can all apply. An institution may submit more than one application if each is "scientifically distinct."
Strategy
Pick the center type by your cohort. If your strongest asset is an EHR-linked infection cohort, such as a health system with longitudinal Lyme, RSV, or post-acute infection data, apply as a CIDSB. If your strongest asset is single-cell or multiomic expertise on AMP tissue, apply as an SBI. Trying to straddle both reads as unfocused, and the NOFO forbids it.
Build three Research Projects that need each other. For CIDSB, a strong design pairs one project on chronic disease increasing infection susceptibility, one on infection driving chronic or post-acute disease, and one on combined trajectories over time. The NOFO practically outlines this when it asks how the center will "explore both aspects of the interactions." Shared cores should connect all three.
Make validation real. The Validation and Translation Core must test "model precision and reproducibility" using cell-based assays, NAMs, animal models, and real-world data. Reviewers will look for predictions that can be falsified, with a named assay and a named decision point, not a plan to "validate key findings."
Write the data plan for named repositories. Data must go to NIH-approved repositories. ImmPort, the Bioinformatics Resource Centers, and the Immune Epitope Database are named, and data will be indexed in the NIAID Data Ecosystem. Commit to specific repositories in the Data Management and Sharing Plan in the Overall component.
Talk to program staff by December. NIH encourages early contact. The scientific contacts are listed by institute, and NIAID's general inbox is niaidogat@mail.nih.gov. With a single receipt date, and SAM and eRA Commons registrations that the NOFO warns "can take 6 weeks or more," a team should settle its center type, cohort access, and core leads before the January 18 submission window opens.
For context on how NIAID is structuring other large FY2028 cooperative agreements, see our analysis of the Immune Tolerance Network recompetition.
A U19 is mostly a project-management challenge with science inside it: nine components, multiple institutions, and one deadline. Granted can help you draft the Overall narrative and keep cores and projects consistent with each other between now and February 18.